🇨🇳
中文原文
本研究采用随机对照试验设计，使用了⚠️ 中式表达 246 例符合入组标准的 2型糖尿病📗 MeSH术语 患者，对比新型降糖药与安慰剂的疗效和安全性。
主要终点是治疗 24 周后 糖化血红蛋白📗 MeSH术语 相对于基线的变化✂️ 可精简。
次要终点包括空腹血糖、体重及不良事件发生率。所有患者均签署知情同意书，研究方案获得伦理委员会批准。
🇺🇸
英文润色
This randomized controlled trial enrolled 246 patients with type 2 diabetes mellitusMeSH who met the inclusion criteria to compare the efficacy and safety of a novel antidiabetic agent versus placebo.
The primary endpoint was the change in HbA1cMeSH from baseline at 24 weeks.
Secondary endpoints included fasting plasma glucose, body weight, and incidence of adverse events. All patients provided written informed consent, and the study protocol was approved by the ethics committee.